Expanded Access Programs Explained: How to Get Experimental Treatments Legally
Share
When no approved treatments remain and a clinical trial isn’t possible, Expanded Access Programs (often called compassionate use) can provide a legal pathway to investigational therapies.
What Exactly Is Expanded Access?
According to the U.S. Food and Drug Administration (FDA), Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or device) outside of a clinical trial when:
- No comparable or satisfactory alternative therapy is available
- The patient cannot enroll in a clinical trial
- The potential benefits justify the potential risks
The FDA reports that it approves the vast majority of Expanded Access requests — over 99% for individual patient requests in recent years.
There are three main categories:
- Individual patient (most common — also called single-patient IND)
- Intermediate-size patient populations (small groups)
- Treatment IND (wider use when a drug is close to approval)
Expanded Access vs. Clinical Trials vs. Right-to-Try
| Pathway | Purpose | Oversight | Who Applies | Key Difference |
|---|---|---|---|---|
| Clinical Trial | Test safety & efficacy | Strict protocol + IRB | Researchers enroll patients | Controlled study |
| Expanded Access | Treatment use | FDA + physician + manufacturer | Doctor files for patient | Compassionate, individualized |
| Right-to-Try | Treatment use | Less FDA involvement | Patient/doctor (post-Phase 1) | Fewer safeguards |
Right-to-Try laws exist in the U.S. but are used far less often because they lack the structured FDA review that Expanded Access provides.
Step-by-Step: How Expanded Access Actually Works
- Doctor and patient discuss options
- Identify the investigational treatment (usually one already in trials)
- Contact the drug manufacturer — they must agree to provide the product
- Physician submits request to FDA (Form 3926 for single-patient cases)
- Institutional Review Board (IRB) approval is usually required
- Treatment begins once all approvals are in place
The entire process can take days to weeks, depending on urgency.
Important Considerations and Potential Challenges
- Costs: The manufacturer often provides the drug for free, but the patient’s insurance or out-of-pocket may cover tests, monitoring, and hospital visits.
- Risks: These are still investigational — side effects are not fully known.
- Data collection: Some safety information is still reported back to the sponsor and FDA.
- Global options: Similar programs exist in the EU (compassionate use), Canada, and other countries — each with its own rules.
Many families don’t realize Expanded Access exists because it is not advertised like standard treatments. It is most commonly used in oncology, rare diseases, and infectious conditions.
Real-World Context
Expanded Access has been used successfully in thousands of cases. For example, it has provided access to promising therapies for certain cancers and genetic disorders years before full approval. However, it is not a guarantee — the manufacturer must be willing and able to supply the product.
If you or a loved one is exploring options beyond standard care, understanding these pathways can open doors that public trial databases alone might miss.
Would you like help researching whether Expanded Access or other pathways might apply to your specific situation? Our team offers a free case assessment (no obligation) to review your records and outline realistic options. Many families find this step brings clarity quickly.